Mayne Pharma to Highlight Growth Strategy at ASX SMIDcaps Conference

An announcement from Mayne Pharma Group ( (AU:MYX) ) is now available.

Mayne Pharma has announced it will present at the ASX SMIDcaps Conference in Sydney on 25 March 2026, where CEO Aaron Gray will brief investors on recent progress in women’s health and dermatology. The update will also highlight how the company’s new DistributeRx launch is improving the pathway from prescription to patient and outline strategic priorities for the remainder of 2026, reinforcing its positioning among emerging ASX-listed healthcare stocks.

The most recent analyst rating on (AU:MYX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group is an ASX-listed specialty pharmaceutical company focused on commercialising novel medicines that are safer, better and more accessible for patients. The company is a leader in dermatology and women’s health in the United States, also offering global contract development and manufacturing services, underpinned by a 40-year track record in oral drug delivery innovation.

YTD Price Performance: -23.47%

Average Trading Volume: 468,152

Technical Sentiment Signal: Sell

Current Market Cap: A$193.4M

For a thorough assessment of MYX stock, go to TipRanks’ Stock Analysis page.